- Title
- Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial
- Creator
- Ewertz, Marianne; Gray, Kathryn P.; Gelber, Richard D.; Colleoni, Marco; Láng, István; Smith, Ian E.; Coates, Alan S.; Goldhirsch, Aron; Mouridsen, Henning T.; Regan, Meredith M.; Ejlertsen, Bent; Price, Karen N.; Thürlimann, Beat; Bonnefoi, Hervé; Forbes, John F.; Paridaens, Robert J.; Rabaglio, Manuela
- Relation
- Journal of Clinical Oncology Vol. 30, Issue 32, p. 3967-3975
- Publisher Link
- http://dx.doi.org/10.1200/JCO.2011.40.8666
- Publisher
- American Society of Clinical Oncology
- Resource Type
- journal article
- Date
- 2012
- Description
- Purpose: To examine the association of baseline body mass index (BMI) with the risk of recurrence or death in postmenopausal women with early-stage breast cancer receiving adjuvant tamoxifen or letrozole in the Breast International Group (BIG) 1-98 trial at 8.7 years of median follow-up. Patients and Methods: This report analyzes 4,760 patients with breast cancer randomly assigned to 5 years of monotherapy with letrozole or tamoxifen in the BIG 1-98 trial with available information on BMI at randomization. Multivariable Cox modeling assessed the association of BMI with disease-free survival, overall survival (OS), breast cancer-free interval, and distant recurrence-free interval and tested for treatment-by-BMI interaction. Median follow-up was 8.7 years. Results: Seventeen percent of patients have died. Obese patients (BMI >= 30 kg/m²) had slightly poorer OS (hazard ratio [HR] = 1.19; 95% CI, 0.99 to 1.44) than patients with normal BMI (< 25 kg/m²), whereas no trend in OS was observed in overweight (BMI 25 to < 30 kg/m²) versus normal-weight patients (HR = 1.02; 95% CI, 0.86 to 1.20). Treatment-by-BMI interactions were not statistically significant. The HRs for OS comparing obese versus normal BMI were HR = 1.22 (95% CI, 0.93 to 1.60) and HR = 1.18 (95% CI, 0.91 to 1.52) in the letrozole and tamoxifen groups, respectively. Conclusion: There was no evidence that the benefit of letrozole over tamoxifen differed according to patients' BMI.
- Subject
- body mass index; postmenopausal women; obesity; breast cancer
- Identifier
- http://hdl.handle.net/1959.13/1307301
- Identifier
- uon:21393
- Identifier
- ISSN:0732-183X
- Language
- eng
- Reviewed
- Hits: 18538
- Visitors: 8166
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|